Long-Term Prognosis of Patients with Myocardial Infarction Type 1 and Type 2 with and without Involvement of Coronary Vasospasm
- PMID: 32498247
- PMCID: PMC7356040
- DOI: 10.3390/jcm9061686
Long-Term Prognosis of Patients with Myocardial Infarction Type 1 and Type 2 with and without Involvement of Coronary Vasospasm
Abstract
While prognoses in relation to myocardial infarction (MI) type have been elucidated in past reports, the results were not consistent, perhaps due to occurrence of Type 2 MI with CVS and its mortality. The Japanese registry of acute Myocardial Infarction diagnosed by Universal Definition (J-MINUET) is a prospective multicenter registry in Japan. In contrast to thromboembolic event-related Type 1 myocardial infarction (MI), clinical features of Type 2 MI, including coronary vasospasm (CVS), are varied due to the heterogeneous nature of its development. To elucidate the MI type-related all-cause mortality, 2989 consecutive patients with AMI were stratified as Type 1 MI, Type 2 MI with CVS, and Type 2 MI with non-CVS. Most patients (n = 2834; 94.8%) were classified as Type 1 MI and 155 patients (5.2%) were classified as Type 2 MI. Of the Type 2 MI patients, 87 (56% of Type 2 MI) were diagnosed as MI with CVS. Although the 3-year mortality was comparable between Type 1 and Type 2 MI patients, significant differences were observed between Type 2 MI with CVS and with non-CVS (3.4% and 22.1%, p < 0.001). Among Japanese patients with AMI, mortality rates between Type 1 MI and Type 2 MI are comparable, but further stratification of Type 2 MI (with or without CVS) may be useful in predicting the prognosis of patients with Type 2 MI.
Keywords: acute myocardial infarction; clinical outcomes; coronary vasospasm; universal definition of myocardial infarction.
Conflict of interest statement
K.S. (Kenji Sakamoto) has received a research grant from Daiichi Sankyo Co., Ltd. K.K. (Koichi Kaikita) has received several research grants from Bayer Yakuhin, Ltd., Daiichi Sankyo Co., Ltd., Novartis Pharma K.K., and SBI Pharma K.K. K.T. (Kenichi Tsujita) has received honoraria from Amgen Astellas Bio Pharma K.K., Bayer Yakuhin, Ltd., Daiichi Sankyo Co., Ltd., MSD K.K., Sanofi K.K., and has received several research grants from AstraZeneca K.K., Astellas Pharma Inc., Bayer Yakuhin, Ltd., Boehringer Ingelheim Japan., Boston Scientific Japan K.K., Chugai Pharmaceutical Co, Ltd., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Kowa Pharmaceutical Co. Ltd., Mitsubishi Tanabe Pharma Co., MSD K.K., Pfizer Japan Inc., Sanofi K.K., Shionogi & Co., Ltd., and Takeda Pharmaceutical Co., Ltd. Y.O. has received several research grants from Bayer Yakuhin, Ltd., Research Institute for Production Development, Daiichi-Sankyo Co., Ltd., and Dainippon Sumitomo Co., Ltd. K.K. (Kazuo Kimura) has received honoraria from Astrazeneca, Toa Eiyo Ltd., MSD K.K., Bayer Yakuhin, Ltd., Daiichi-Sankyo Co., Ltd. and has received several research grants from MSD K.K., Daiichi-Sankyo Co., Ltd., Ono Pharmaceutical Co., Pfizer Japan Inc., Bayer Yakuhin Ltd., Takeda Pharmaceutical Co., Ltd., Boehringer Ingelheim Japan, Tanabe Mitsubishi, and Astellas Pharma Inc. W.S. has received honoraria from Daiichi-Sankyo Co., Ltd., Boehringer Ingelheim Japan, Bayer Yakuhin Ltd., Bristole, Ono Pharmaceutical Co., and received several research grants from Daiichi-Sankyo Co., Ltd., Boehringer Ingelheim Japan, Ono Pharmaceutical Co., Otsuka Pharmaceutical Co., Eisai Co., Mitsubishi Tanabe Pharma Co., Asterllas Pharma Inc., and St Jude Medical. Y.S. (Yoshihiko Saito) has received honoraria from Otsuka Pharmaceutical Co., Ltd., Kowa Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Mitsubishi Tanabe Pharma Co., Pfizer Japan Inc., Novartis Pharma K.K. and received several research grants from Takeda Pharmaceutical Co., Ltd., Teijin Pharma Ltd., Ono Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Co., Eisai Co., Ltd., ZERIA Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Dainippon Sumitomo Pharma Co., Ltd., Kyowa Hakko Kirin Co., Ltd., Astellas Pharma Inc., Daiichi Sankyo Co., Ltd., and Boston Scientific Japan K.K. T.M. (Toshiaki Mano) has received a research grant from Abbot Vascular Japan. K.T. (Kengo Tanabe) has received honoraria from Abbot vascular Japan, Mitsubishi Tanabe Pharma Co., Daiichi Sankyo Co., Ltd. and has received several research grants from Kaneka and Terumo. M.I. has received honoraria from Bayer Yakuhin Ltd., MSD K.K., Astra Zeneca, Astellas Pharma Inc. and has received several research grants from Abbott Vascular Japan, Boston Scientific Japan K.K., Sanofi K.K., MSD K.K., Astellas Pharma Inc., Bayer Yakuhin Ltd., Pfizer, Daiichi Sankyo Co., Ltd., MID, and Goodman. No funders have any role in this study.
Figures



Similar articles
-
Clinical Presentation, Management and Outcome of Japanese Patients With Acute Myocardial Infarction in the Troponin Era - Japanese Registry of Acute Myocardial Infarction Diagnosed by Universal Definition (J-MINUET) -.Circ J. 2015;79(6):1255-62. doi: 10.1253/circj.CJ-15-0217. Epub 2015 Apr 24. Circ J. 2015. PMID: 25912696
-
Validation of the atherothrombotic risk score for secondary prevention in patients with acute myocardial infarction: the J-MINUET study.Heart Vessels. 2021 Oct;36(10):1506-1513. doi: 10.1007/s00380-021-01840-z. Epub 2021 Apr 21. Heart Vessels. 2021. PMID: 33880614
-
Association of onset-season with characteristics and long-term outcomes in acute myocardial infarction patients: results from the Japanese registry of acute myocardial infarction diagnosed by universal definition (J-MINUET) substudy.Heart Vessels. 2019 Dec;34(12):1899-1908. doi: 10.1007/s00380-019-01426-w. Epub 2019 May 25. Heart Vessels. 2019. PMID: 31129873
-
Recent advances in the diagnosis and treatment of acute myocardial infarction.World J Cardiol. 2015 May 26;7(5):243-76. doi: 10.4330/wjc.v7.i5.243. World J Cardiol. 2015. PMID: 26015857 Free PMC article. Review.
-
Consideration of a new definition of clinically relevant myocardial infarction after coronary revascularization: an expert consensus document from the Society for Cardiovascular Angiography and Interventions (SCAI).J Am Coll Cardiol. 2013 Oct 22;62(17):1563-70. doi: 10.1016/j.jacc.2013.08.720. J Am Coll Cardiol. 2013. PMID: 24135581 Free PMC article.
Cited by
-
Long-term clinical outcomes of type 1 vs. type 2 myocardial infarction in patients who underwent angiography: data from the Korea acute myocardial infarction-national institute of health registry.Cardiovasc Diagn Ther. 2022 Feb;12(1):55-66. doi: 10.21037/cdt-21-434. Cardiovasc Diagn Ther. 2022. PMID: 35282670 Free PMC article.
-
COVID-19 and myocardial injury: Targeting elevated biomarkers for potential novel therapies.Clinics (Sao Paulo). 2024 Aug 27;79:100473. doi: 10.1016/j.clinsp.2024.100473. eCollection 2024. Clinics (Sao Paulo). 2024. PMID: 39197405 Free PMC article.
-
Analysis of Anti-Arrhythmic Impacts of Crocin through Estimation of Expression of Cx43 in Myocardial Infarction Using a Rat Animal Model.ACS Omega. 2022 Oct 11;7(42):37164-37169. doi: 10.1021/acsomega.2c03158. eCollection 2022 Oct 25. ACS Omega. 2022. PMID: 36312395 Free PMC article.
-
To the Future and Beyond: Recent Advances in the Application of Percutaneous Coronary Intervention.J Clin Med. 2021 Jan 6;10(2):177. doi: 10.3390/jcm10020177. J Clin Med. 2021. PMID: 33419034 Free PMC article.
-
Diagnostic features, management and prognosis of type 2 myocardial infarction compared to type 1 myocardial infarction: a systematic review and meta-analysis.BMJ Open. 2022 Feb 17;12(2):e055755. doi: 10.1136/bmjopen-2021-055755. BMJ Open. 2022. PMID: 35177458 Free PMC article.
References
-
- The Joint European Society of Cardiology/American College of Cardiology Committee Myocardial infarction redefined—A consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction. Eur. Heart J. 2000;21:1502–1513. doi: 10.1053/euhj.2000.2305. - DOI - PubMed
-
- Thygesen K., Alpert J.S., White H.D. Universal definition of myocardial infarction. Eur. Heart J. 2007;28:2525–2538. - PubMed
-
- Thygesen K., Alpert J.S., Jaffe A.S., Chaitman B.R., Bax J.J., Morrow D.A., White H.D., Executive Group on behalf of the Joint European Society of Cardiology /American College of Cardiology /American Heart Association /World Heart Federation Task Force for the Universal Definition of Myocardial, I. Fourth universal definition of myocardial infarction (2018) Eur. Heart J. 2018;40:237–269. doi: 10.1093/eurheartj/ehy462. - DOI - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous